US OptionsDetailed Quotes
FBIO250117C2500
- 0.04
- 0.000.00%
15min DelayClose Jan 17 16:00 ET
0.00High0.00Low
0.00Open0.04Pre Close0 Volume3.72K Open Interest2.50Strike Price0.00Turnover9945.72%IV40.33%PremiumJan 17, 2025Expiry Date0.00Intrinsic Value100Multiplier-4DDays to Expiry0.04Extrinsic Value100Contract SizeAmericanOptions Type0.1687Delta0.5038Gamma45.25Leverage Ratio-23.6080Theta0.0000Rho7.63Eff Leverage0.0000Vega
Fortress Biotech Stock Discussion
Sign in to post a comment
$Fortress Biotech (FBIO.US)$ Item 8.01. Other Events.
Cyprium Therapeutics, Inc. (“Cyprium”), a majority-owned subsidiary of Fortress Biotech, Inc. (the “Company” or “Fortress”), was notified by Sentynl Therapeutics, Inc. (“Sentynl”) that the U.S. Food and Drug Administration (the “FDA”) extended the target action date for the New Drug Application (“NDA”) for CUTX-101 (Copper Histidinate) to September 30, 2025. Sentynl assumed full responsibility for the development and commercialization...
Cyprium Therapeutics, Inc. (“Cyprium”), a majority-owned subsidiary of Fortress Biotech, Inc. (the “Company” or “Fortress”), was notified by Sentynl Therapeutics, Inc. (“Sentynl”) that the U.S. Food and Drug Administration (the “FDA”) extended the target action date for the New Drug Application (“NDA”) for CUTX-101 (Copper Histidinate) to September 30, 2025. Sentynl assumed full responsibility for the development and commercialization...
6
$Fortress Biotech (FBIO.US)$
Fortress Biotech and Cyprium Therapeutics Announce U.S. FDA Acceptance and Priority Review of NDA for CUTX-101 for Treatment of Menkes Disease
Monday, 6th January at 8:00 am
Priority review granted for CUTX-101 with PDUFA target action date set for June 30, 2025
Cyprium is eligible to receive royalties and up to $129 million in aggregate development and sales milestones
Cyprium also retains ownership over any Priority Review Voucher that may be issued at NDA appro...
Fortress Biotech and Cyprium Therapeutics Announce U.S. FDA Acceptance and Priority Review of NDA for CUTX-101 for Treatment of Menkes Disease
Monday, 6th January at 8:00 am
Priority review granted for CUTX-101 with PDUFA target action date set for June 30, 2025
Cyprium is eligible to receive royalties and up to $129 million in aggregate development and sales milestones
Cyprium also retains ownership over any Priority Review Voucher that may be issued at NDA appro...
$Gorilla Technology (GRRR.US)$ PR: CEO will have interview with Red Chip Small Stock, Big Money show on Sat Dec 14. Reports on CEO on X that they have been selected from the shortlist for the $438M deal in SE Asia. Low float. $23.2M cash good for 12 months
$Checkpoint Therapeutics (CKPT.US)$ $Fortress Biotech (FBIO.US)$ FDA approval of drug for metastatic cutaneous squamous cell carcinoma. This drug is the first and only progr...
$Checkpoint Therapeutics (CKPT.US)$ $Fortress Biotech (FBIO.US)$ FDA approval of drug for metastatic cutaneous squamous cell carcinoma. This drug is the first and only progr...
31
31
![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined"){kind=small}
$Fortress Biotech (FBIO.US)$
Checkpoint Therapeutics Announces FDA Approval of UNLOXCYT™ (cosibelimab-ipdl)
19 seconds ago, 3:15 PM PST
Via GlobeNewswire
CKPTFBIO
Share
WALTHAM, Mass., Dec. 13, 2024 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. ("Checkpoint") (NASDAQ:CKPT), today announced that the U.S. Food and Drug Administration ("FDA") has approved UNLOXCYT™ (cosibelimab-ipdl) for the treatment of adults with metastatic cutaneous squamous cell carcinoma ("cSCC") or locally advanced c...
Checkpoint Therapeutics Announces FDA Approval of UNLOXCYT™ (cosibelimab-ipdl)
19 seconds ago, 3:15 PM PST
Via GlobeNewswire
CKPTFBIO
Share
WALTHAM, Mass., Dec. 13, 2024 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. ("Checkpoint") (NASDAQ:CKPT), today announced that the U.S. Food and Drug Administration ("FDA") has approved UNLOXCYT™ (cosibelimab-ipdl) for the treatment of adults with metastatic cutaneous squamous cell carcinoma ("cSCC") or locally advanced c...
$Fortress Biotech (FBIO.US)$ over here, slow and low volume
1
1
$Fortress Biotech (FBIO.US)$ On FDA PDUFA Calendar for BLA of DFD-29 for treatment of lesions and erythema of rosacea in adults on 11/04/2024![]()
2
4
$Fortress Biotech (FBIO.US)$ should pump a little off MBIO if it gets running regular hours by Tutes
No comment yet
10baggerbamm : I would tell you this I don't like these little micro cap small cap biotech but this has a nice sine wave pattern to it and if there was like over smoking hot woman that would give me a drink when I would place a trade you know like at a casino I probably would throw a trade in just cuz I like the look of the pattern that I'm seeing and I don't mean what she would be wearing I mean the channel that exists where it looks like there's going to be a big cycle backup so not telling you to buy it not telling you not to buy it I don't know shit about this company I just clicked on and I'm like you know what that looks pretty damn good
Trytosaveabit OP 10baggerbamm : Hehehe! I’m picking up what yer layin down! Hehehe! The have been split off, partnered up, sold and teamed up! Got lots of tentacles in a lot of places! At least last time I went deep they did! Hehehe
10baggerbamm Trytosaveabit OP : good luck to you I hope you make money like I said I saw this and I like channel surfing I do it all the time. I just won't do this one but good luck to you I think you're going to make a pretty good amount of money I think it'll cycle back and fill that upward trend to the upper resistance maybe in a month or so
Trytosaveabit OP 10baggerbamm : Thank you! But I know this ticker to well! It 90% of the time don’t follow typical chart patterns that most do! I’m just not ready to enter yet! But thank you! And GL with whatever you are in.
10baggerbamm Trytosaveabit OP : well right now a girl I just picked up at the bar...
View more comments...